FDA poised to increase China inspections

Gareth Mcdonald from in-pharmatechnologist.com shared his views on the impact of FDA committing a forecasted $5 million of its newly approved budget to visit Chinese drug plants. The reason for the increase attention in China is that FDA wants to focus on facilities that produce drugs and drug ingredients that pose the greatest risk to patients in the United States. Also on the agenda will be training of Chinese health authorities to enhance their ability to regulate pharmaceutical products exported to the U.S. To read the full article click here.